4.
Anti-angiogenic drugs and targeted therapies for NSCLC
| Regimen | Dose | Time |
| Anti-angiogenic drugs | ||
| Endostatin | 7.5 mg/m2 | d1−d14, 21 d/cycle |
| Bevacizumab | 7.5−15 mg/kg | d1, 21 d/cycle |
| Targeted therapies | ||
| Gefitinib | 250 mg | Qd |
| Erlotinib | 150 mg | Qd |
| Icotinib | 125 mg | Tid |
| Alfatinib | 40 mg | Qd |
| Crizotinib | 250 mg | Bid |